Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial

Susan E Carlson, Byron J Gajewski, Christina J Valentine, Elizabeth H Kerling, Carl P Weiner, Michael Cackovic, Catalin S Buhimschi, Lynette K Rogers, Scott A Sands, Alexandra R Brown, Dinesh Pal Mudaranthakam, Sarah A Crawford, Emily A DeFranco, Susan E Carlson, Byron J Gajewski, Christina J Valentine, Elizabeth H Kerling, Carl P Weiner, Michael Cackovic, Catalin S Buhimschi, Lynette K Rogers, Scott A Sands, Alexandra R Brown, Dinesh Pal Mudaranthakam, Sarah A Crawford, Emily A DeFranco

Abstract

Background: Several meta analyses have concluded n-3 fatty acids, including docosahexaenoic acid (DHA), reduce early preterm birth (EPB, < 34 weeks), however, the amount of DHA required is unclear. We hypothesized that 1000 mg DHA per day would be superior to 200 mg, the amount in most prenatal supplements.

Methods: This randomised, multicentre, double-blind, adaptive-design, superiority trial was conducted in three USA medical centres. Women with singleton pregnancies and 12 to 20 weeks gestation were eligible. randomization was generated in SAS® by site in blocks of 4. The planned adaptive design periodically generated allocation ratios favoring the better performing dose. Managing study personnel were blind to treatment until 30 days after the last birth. The primary outcome was EPB by dose and by enrolment DHA status (low/high). Bayesian posterior probabilities (pp) were determined for planned efficacy and safety outcomes using intention-to-treat. The study is registered with ClinicalTrials.gov (NCT02626299) and closed to enrolment.

Findings: Eleven hundred participants (1000 mg, n = 576; 200 mg, n = 524) were enrolled between June 8, 2016 and March 13, 2020 with the last birth September 5, 2020. 1032 (n = 540 and n = 492) were included in the primary analyses. The higher dose had a lower EPB rate [1.7% (9/540) vs 2.4% (12/492), pp=0.81] especially if participants had low DHA status at enrolment [2.0% (5/249) vs 4.1%, (9/219), pp=0.93]. Participants with high enrolment DHA status did not realize a dose effect [1000 mg: 1.4% (4/289); 200 mg: 1.1% (3/271), pp = 0.57]. The higher dose was associated with fewer serious adverse events (maternal: chorioamnionitis, premature rupture of membranes and pyelonephritis; neonatal: feeding, genitourinary and neurologic problems, all pp>0.90).

Interpretation: Clinicians could consider prescribing 1000 mg DHA daily during pregnancy to reduce EPB in women with low DHA status if they are able to screen for DHA.

Funding: The National Institutes of Health Child Health and Human Development (NICHD) funded the study. Life's DHA™-S oil, DSM Nutritional Products LLC, Switzerland provided all capsules.

Keywords: Docosahexaenoic acid (DHA) amount; Early preterm birth; Gestation less than 34 weeks; Pregnancy.

Conflict of interest statement

None.

© 2021 The Author(s).

Figures

Fig. 1
Fig. 1
Trial profile.
Fig. 2
Fig. 2
Primary efficacy analysis by group Bayesian posterior probability (pp) =0.91 for less early preterm birth (EPB) with the higher dose. The denominator for the 200 mg dose is 492 and for the 1000 mg dose is 540.
Fig. 3
Fig. 3
Efficacy analysis in participants with low DHA status at enrolment (red blood cell DHA

References

    1. Martin J.A., Hamilton B.E., Osterman M.J.K., Driscoll A.K. Births: national vital statistics reports. Final Data. 2018 for.
    1. Beam A.L., Fried I., Palmer N., Agniel D., Brat G., Fox K. Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016. J Perinatol Off J Calif Perinat Assoc. 2020;40(7):1091–1099.
    1. Weiner C.P., Mason C.W., Dong Y., Buhimschi I.A., Swaan P.W., Buhimschi C.S. Human effector/initiator gene sets that regulate myometrial contractility during term and preterm labor. Am J Obstet Gynecol. 2010;202(5):474. e1-20.
    1. Middleton P., Gomersall J.C., Gould J.F., Shepherd E., Olsen S.F., Makrides M. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev. 2018;11(11)
    1. Brenna J.T., Lapillonne A. Background paper on fat and fatty acid requirements during pregnancy and lactation. Ann Nutr Metab. 2009;55(1–3):97–122.
    1. Carlson S.E., Colombo J., Gajewski B.J., Gustafson K.M., Mundy D., Yeast J. DHA supplementation and pregnancy outcomes. Am J Clin Nutr. 2013;97(4):808–815.
    1. Araujo P., Kjellevold M., Nerhus I., Dahl L., Aakre I., Moe V. Fatty acid reference intervals in red blood cells among pregnant women in norway-cross sectional data from the 'little in norway' cohort. Nutrients. 2020;12(10)
    1. WHO and FAO joint consultation: fats and oils in human nutrition. Nutr Rev. 1995;53(7):202–205.
    1. Carlson S.E., Gajewski B.J., Valentine C.J., Rogers L.K., Weiner C.P., DeFranco E.A. Assessment of DHA on reducing early preterm birth: the ADORE randomized controlled trial protocol. BMC Pregnancy Childbirth. 2017;17(1):62.
    1. Berry S., Carlin B.P., Lee J.J., Muller P. CRC Press; Boca Raton, FL: 2011. Bayesian Adaptive Methods for Clinical Trials.
    1. American college of obstetricians and gynecologists committee opinion: committee on obstetric practice. Number. March 2017;688
    1. Simmonds L.A., Sullivan T.R., Skubisz M., Middleton P.F., Best K.P., Yelland L.N. Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm birth: exploratory analysis of a randomised controlled trial. BJOG Int J Obstet Gynaecol. 2020;127(8):975–981.
    1. Makrides M., Best K., Yelland L., McPhee A., Zhou S., Quinlivan J. A randomized trial of prenatal n-3 fatty acid supplementation and preterm delivery. The New Engl J Med. 2019;381(11):1035–1045.
    1. Gajewski B.J., Reese C.S., Colombo J., Carlson S.E. Commensurate priors on a finite mixture model for incorporating repository data in clinical trials. Stat Biopharm Res. 2016;8(2):151–160.
    1. Berry S.M., Berry D.A. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics. 2004;60(2):418–426.
    1. Makrides M., Gibson R.A., McPhee A.J. Effect of dha supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. 2010;304(15):1675–1683.
    1. Olsen S.F., Secher N.J., Tabor A., Weber T., Walker J.J., Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. fish oil trials in pregnancy (FOTIP) team. BJOG Int J Obstet Gynaecol. 2000;107(3):382–395.
    1. Harper M., Thom E., Klebanoff M.A., Thorp J., Sorokin Y., Varner M.W. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial. Obstet Gynecol. 2010;115(2):234–242. Pt 1.
    1. Makrides M., Duley L., Olsen S.F. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006;3
    1. Imhoff-Kunsch B., Briggs V., Goldenberg T., Ramakrishnan U. Effect of n-3 long-chain polyunsaturated fatty acid intake during pregnancy on maternal, infant, and child health outcomes: a systematic review. Paediatr Perinat Epidemiol. 2012;26(1):91–107. Suppl.
    1. Johnson R.K., Driscoll P., Goran M.I. Comparison of multiple-pass 24-hour recall estimates of energy intake with total energy expenditure determined by the doubly labeled water method in young children. J Am Diet Assoc. 1996;96(11):1140–1144.
    1. Buhimschi C.S., Baumbusch M.A., Dulay A.T., Oliver E.A., Lee S., Zhao G. Characterization of RAGE, HMGB1, and S100beta in inflammation-induced preterm birth and fetal tissue injury. Am J Pathol. 2009;175(3):958–975.
    1. Defranco E.A., Jacobs T.S., Plunkett J., Chaudhari B.P., Huettner P.C., Muglia L.J. Placental pathologic aberrations in cases of familial idiopathic spontaneous preterm birth. Placenta. 2011;32(5):386–390.
    1. Ngo T.T.M., Moufarrej M.N., Rasmussen M.H., Camunas-Soler J., Pan W., Okamoto J. Noninvasive blood tests for fetal development predict gestational age and preterm delivery. Science. 2018;360(6393):1133–1136. New York, NY.
    1. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–137.
    1. Aung M.T., Yu Y., Ferguson K.K., Cantonwine D.E., Zeng L., McElrath T.F. Prediction and associations of preterm birth and its subtypes with eicosanoid enzymatic pathways and inflammatory markers. Sci Rep. 2019;9(1):17049.
    1. Martin J.A., Hamilton B.E., Osterman M.J., Curtin S.C., Matthews T.J. Births: final data for 2013. national vital statistics reports: from the centers for disease control and prevention, national center for health statistics. Nat Vital Stat Syst. 2015;64(1):1–65.
    1. Olsen S.F., Halldorsson T.L., Thorne-Lyman A.L., Strom M., Gortz S., Granstrom C., Nielsen P.H., Wohlfahrt J., Lykke J.A., Langhoff-Roos J., Cohen A.S., Furtado J.D., Giovanucci E.L., Zhou W. Plasma concentrations of long chain n-3 fatty acids in early and mid-pregnancy and risk of early preterm birth. EBioMed. 2018;35:325–333.
    1. Beck S., Wojdyla D., Say L., Betran A.P., Merialdi M., Requejo J.H., Rubens C., Menon R., Van Look P.F.A. The worldwide inicdence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ. 2010;88:31–38.
    1. Stark K.D., Van Elswyk M.E., Higgins M.R., Weatherford C.A., Salem N. Global survey of the omega-3 fatty acids, docosahexaneoic acid and eicospentaneoic acid in the blood stream of healthy adutls. Prog Lipid Res. 2016;63:132–152.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir